Efficacy End Points For PNH Treatment

EP: 1.PNH Overview and Pathophysiology

EP: 2.Intravascular and Extravascular Hemolysis MoA in PNH

EP: 3.Utilizing Health Information Technology to Bridge Gaps in PNH Treatment Programming

EP: 4.Key Treatment Considerations for Patients Diagnosed With PNH

EP: 5.Complement System Role in PNH Treatment Approach

EP: 6.Eculizumab Impact on PNH Treatment Landscape and Unmet Needs in PNH Management

Now Viewing

EP: 7.Efficacy End Points For PNH Treatment

EP: 8.Efficacy and Safety Trials Results of Complement Inhibitors

EP: 9.Treatment Adherence and Cost Considerations Surrounding Various Routes of PNH Treatment Administration

EP: 10.Investigational Therapies Paving New PNH Treatment Pathways

EP: 11.Key Financial Factors Associated With Typical PNH Treatment Journey

EP: 12.Navigating Transfusion Requirements in PNH Treatment

EP: 13.Considerations for Managing PNH Treatment Complications

EP: 14.Infection Risk Management Counseling For Patients Receiving Treatment for PNH

EP: 15.Ensuring PNH Treatment Access and Adherence to Therapies

EP: 16.Financial Considerations Influencing Treatment Strategies in PNH Treatment Pathway

Video content above is prompted by the following:

• Please describe the significance of the different efficacy end points explored for paroxysmal nocturnal hemoglobinuria treatments (eg, lactate dehydrogenase levels, hemoglobin concentrations, absolute reticulocyte count (ARC) levels, transfusion avoidance, Functional Assessment of Chronic Illness Therapy–Fatigue).